25Sep

SpeeDx and Diagen sign new distribution agreement for Scandinavia

SYDNEY, AUSTRALIA – (Sept 19, 2017). SpeeDx Pty, Ltd. has announced a distribution agreement with Diagen, a leading Scandinavian clinical laboratory supplier specialising in diagnostic products. This agreement will open important sales channels in Sweden, Norway and Denmark for SpeeDx’s PlexPCR® and unique, multiplexed ResistancePlus® real-time polymerase chain reaction product lines.

Diagen has a strong reputation for providing advanced sales and support to hospitals, universities and research laboratories across Scandinavia. Using SpeeDx’s proprietary technology, the PlexPCR range will allow Diagen’s customers to obtain complex diagnostic information on sexually transmitted infections or other infectious diseases from a single, cost-effective test. The agreement will also give them access to the groundbreaking ResistancePlus MG assay. This is the first CE-IVD test to simultaneously detect Mycoplasma genitalium and genetic markers for azithromycin resistance, as recommended by the new European guidelines on M. genitalium resistance screening in the management of non-gonococcal urethritis.

“Scandinavia is home to some important thought leaders influencing sexual health and STI testing practices across Europe,” said Colin Denver, CEO of SpeeDx. “We see our partnership with Diagen as key to offering the best service to laboratories across these important markets.” 

About SpeeDx

Founded in 2009, SpeeDx is an Australian-based private company with offices in London and distributors across Europe. SpeeDx specializes in molecular diagnostic solutions that go beyond simple detection to offer comprehensive information for improved patient management. Innovative real-time polymerase chain reaction (qPCR) technology has driven market-leading multiplex detection and priming strategies. Product portfolios focus on multiplex diagnostics for sexually transmitted infection (STI), antibiotic resistance markers, and respiratory disease. Currently, SpeeDx markets the only CE-marked and TGA approved commercial molecular test for the STI M. genitalium (ResistancePlus™ MG) that combines detection of the disease with detection of markers for antibiotic resistance. For more information on about SpeeDx please see: http://plexpcr.com

About Diagen

Diagen AS is a supplier and consulting company within the laboratory field. In addition to our specialty in diagnostics and genetic engineering, we deliver advanced and fully automated instruments within routine diagnostics and life sciences across the Nordic region. The company operates consultancy, sales, marketing, technical service and support. The company markets products from reputable manufacturers worldwide.

Related

EKF Publishes Guide to Good Capillary Blood Sampling

Incorrect capillary blood sampling is most common reason for inaccurate POC hemoglobin results

Read More >

OGT pushes forward hybridisation-based targeted sequencing

Oxford, UK – 25 May 2017. Oxford Gene Technology (OGT), The Molecular Genetics Company, has made se...

Read More >

Strategic Partnership for New Bladder Cancer Diagnostic Test in the UK

Alpha Laboratories Ltd. (Eastleigh, UK) is delighted to have been appointed as the exclusive distrib...

Read More >

OGT further expands global direct sales and support into Asia-Pacific region

Following successful European rollout, more customers to benefit from enhanced local sales and suppo...

Read More >

SpeeDx Receives CE-IVD Mark for ResistancePlus® GC

New molecular assay enables rapid antibiotic resistance result to support use of cost effective and ...

Read More >

New Partnership for Biological Sample Transport Solutions

Specialist Laboratory and Diagnostics supply company Alpha Laboratories Ltd. (Eastleigh, UK) is deli...

Read More >